BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JSKN033 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JSKN033\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06770881-2572@assetmemo.bio
DTSTAMP:20261121T005836Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:JSKN033: Phase 1/2 readout est. (NCT06770881)
DESCRIPTION:JSKN033\, phase 1/2.\nStudy: JSKN033 in Chinese Subjects with A
 dvanced Malignant Tumors\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/jskn033#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06770881
URL:https://assetmemo.bio/drug/jskn033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283198-2572@assetmemo.bio
DTSTAMP:20261121T005836Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:JSKN033: Phase 2 readout est. (NCT07283198)
DESCRIPTION:JSKN033\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase
  II Clinical Study to Evaluate the Safety\, Efficacy\, Pharmacokinetics/Ph
 armacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Ca
 ncer\nEstimated primary completion: 30 August 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/jskn033#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07283198
URL:https://assetmemo.bio/drug/jskn033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497074-2572@assetmemo.bio
DTSTAMP:20261121T005836Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:JSKN033: Phase 2 readout est. (NCT07497074)
DESCRIPTION:JSKN033\, phase 2.\nStudy: JSKN033 Combination Therapy in Subje
 cts With Advanced Cervical Cancer\nEstimated primary completion: October 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/jskn033#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07497074
URL:https://assetmemo.bio/drug/jskn033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797153-2572@assetmemo.bio
DTSTAMP:20261121T005836Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:JSKN033: Phase 3 readout est. (NCT07797153)
DESCRIPTION:JSKN033\, phase 3.\nStudy: JSKN033 Versus Investigator's Choice
  of Chemotherapy in Recurrent or Metastatic Cervical Cancer\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/jskn033#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07797153
URL:https://assetmemo.bio/drug/jskn033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
